IOL Chemicals up 5.4% as Q1 PAT jumps 90% on strong margins and API diversification

IOL Chemicals & Pharmaceuticals Ltd shares were in demand on Thursday, rising 5.4% and last traded at Rs 165 after the company released the transcript of its Q1 FY27 earnings call. The detailed commentary appears to have reinforced the positive reaction to a quarter marked by strong profit growth, better margins and visible traction in non-ibuprofen APIs.

What the Q1 FY27 call revealed

The transcript, dated 20 August 2026 (page 1), covers the management’s discussion of results for the quarter ended 30 June 2026.

Chief Financial Officer Pardeep Kumar Khanna told investors (page 3) that for Q1 FY27 the company reported:

• Revenue from operations of INR 756 crores, compared with INR 551 crores in Q1 FY26, “registering a year-on-year growth of 37 percentage.”
• EBITDA of INR 111 crores, versus INR 69.5 crores a year earlier, a growth of 60.7 percentage.
• EBITDA margin improving to 14.6 percentage from 12.4 percentage in the corresponding quarter.
• PAT of INR 64.5 crores, up from INR 34 crores in Q1 FY26, a rise of 89.9%.
• PAT margin rising to 8.4 percentage from 6.1 percentage.

Management repeatedly linked the profitability improvement to “higher operating leverage, better capacity utilization, improved product mix, and continued focus on operational efficiencies” (page 3–4), rather than any one-off gains.

Why the market liked these numbers

The stock’s move after the transcript appears to be driven by three clear messages from the call:

1. Profits are growing faster than revenue
   Investors often look beyond top-line growth to see whether a company is converting that into earnings. In IOL’s case, Q1 FY27 revenue grew 37%, but EBITDA grew 60.7% and PAT 89.9% year-on-year (page 3).

   On page 8, when asked if PAT growth was helped by one-offs, management clarified there was “nothing” extraordinary below EBITDA and that the performance was “except the internal efficiencies.” This reassurance that the earnings jump is largely operational rather than one-time is a strong positive for valuation.

2. Diversification away from ibuprofen is now showing up in the P&L
   A key concern for the market in recent years has been IOL’s dependence on ibuprofen. The call shows that diversification is no longer just a plan; it is contributing meaningfully to growth.

   In his opening remarks (page 2–3), Abhay Raj Singh, Senior Vice President and Company Secretary, highlighted that:

   • Non-ibuprofen products contributed 43% of pharmaceutical revenue in Q1 FY27, up from 36% in Q1 FY26.
   • Revenue from these non-ibuprofen APIs grew 67% year-on-year.

   He named paracetamol, pantoprazole, metformin, fenofibrate and clopidogrel among the key products. Later in the Q&A (pages 6–7), management noted that non-ibuprofen APIs have crossed an “INR 200 crores” quarterly run rate and reiterated a medium-term goal of roughly “50% from ibuprofen and about 50% from non-ibuprofen” within pharma.

   On page 9–10, the team added that in the non-ibuprofen portfolio, paracetamol has “contributed mainly for this increase,” with clopidogrel and pantoprazole also supporting growth, and that they expect broad-based growth across the portfolio.

   This visible shift reduces concentration risk and supports a re-rating narrative, helping explain the stock’s positive reaction.

3. Confident guidance and visibility on growth
   Markets tend to reward not just a strong quarter, but also credible guidance that it can be sustained.

   On page 4, Khanna reiterated that for FY27 the company “remain[s] confident of delivering 15% to 20% revenue growth with an EBITDA margin in the range of 14% to 15% and exports contributing approximately 25% to 30% of the revenue.”

   Later in the Q&A (page 9), he said they “expect revenue growth around 20% and EBITDA 14% to 15%” for the year, based on better capacity utilization, product mix and operational efficiencies, and noted “reasonable visibility into our order book for the coming quarter.”

   Looking beyond FY27, he added (page 9) that they “have a plan to grow about 15% to 20% in top line and EBITDA to 15% to 17% in ‘28 approximately,” while cautioning that this depends on the then-prevailing environment.

   This combination of strong current margins (14.6% in Q1 vs the 14–15% full-year band) and an explicit multi-year growth ambition likely reinforced investor confidence that Q1 is not a one-off spike.

Export push and regulatory gains add to the story

The call also underlined progress on exports and regulatory reach, both of which can support higher realizations and more stable demand:

• Export contribution rose to 28.5% of revenue in Q1 FY27 from 24.4% a year earlier (page 3–4). Management is targeting 25% to 30% exports for FY27 (page 4–5) and described the higher mix as a blend of better product mix, operational efficiency and customer reach (page 14).
• On page 3, Singh pointed out that the NMPA approval for clopidogrel in China “further expands our regulatory reach and market opportunities.”
• Later, management noted that all products have CEP approval, with US FDA approvals for five products and “another two, three products” lined up as formulators’ ANDAs progress (page 10–11). Ibuprofen is already approved in China (page 10–11).

These details strengthen the case that IOL is building a diversified, globally relevant API platform, a theme that tends to be rewarded by the market.

Chemicals segment and new products support earnings quality

The chemicals business also featured positively in the discussion:

• Singh said on page 3 that chemicals delivered “a strong performance” supported by improved realizations, efficient raw material procurement, higher exports and operational efficiencies.
• Khanna added on page 12 that the EBITDA margin of the chemical segment “has been on an upward trend in this quarter,” helped by capacity increases in ethyl acetate and acetic anhydride and higher exports.
• A new product, triacetin, was introduced in the last quarter. Management expects regulatory approvals for it in “two, three quarters” (page 13). The triacetin plant, with 6,000 MTPA capacity, has an estimated revenue potential of around INR 120 crores per year at steady state (page 13–14).

The emphasis on ongoing capex of about INR 200 crores annually, with roughly 60% directed to expansion and new products and 40% to infrastructure and efficiency improvements (page 6–7), reinforces the impression of a growth-focused yet disciplined capital allocation strategy.

Why the move may be more than just headline numbers

The earnings call transcript does not mention valuations or external broker views, so we cannot say how much of the 5.4% move reflects rerating versus earnings upgrades. However, the document clearly:

• Confirms strong YoY growth in revenue, EBITDA and PAT.
• Attributes that growth to sustainable drivers like capacity utilization, product mix and export penetration, while explicitly downplaying one-off inventory gains.
• Shows tangible progress on the long-communicated strategy of diversifying away from ibuprofen.
• Provides quantified guidance for FY27 and an indicative trajectory for FY28.

In the absence of other major news, these factors together appear to be the main drivers behind IOL Chemicals & Pharmaceuticals’ stock moving higher after the Q1 FY27 earnings call transcript was published.